Norhammar A, Bodegard J, Nyström T, et al. - In a real-world population with type 2 diabetes (T2D) like the population of the DECLARE-TIMI 58 study, researchers explored how the cardiovascular (CV) risk benefits of dapagliflozin translate into healthcare costs vs other non-sodium–glucose cotransporter-2 inhibitor glucose-lowering drugs (oGLDs). Patients who met the DECLARE-TIMI 58 inclusion and exclusion criteria and were starting dapagliflozin or oGLDs in Swedish nationwide healthcare registries between 2013 and 2016 were included. There were 24,828 patients who started a new GLD; 6,207 who started dapagliflozin, and 18,621 who started oGLD. Investigators found that dapagliflozin initiation vs oGLD was related to considerably reduced hospital expenses and significantly higher medication charges. Primarily due to lower rates of CV- and T2D-associated complications, dapagliflozin was linked to lower hospital costs vs oGLD.